MedTrace Logo

Ublituximab + Ibrutinib in Select B-cell Malignancies

NCT02013128 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2022-10-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.

Conditions

Interventions

DRUG

Ublituximab

Ublituximab (IV infusion)

DRUG

Ibrutinib

Ibrutinib oral daily dose

Sponsors & Collaborators

  • TG Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jeff Sharman, MD · Willamette Valley Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-06
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02013128 on ClinicalTrials.gov